MedTrace Logo

Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC

NCT06816966 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-02-10

No results posted yet for this study

Summary

This study is a prospective, single-arm, phase Ⅱ trial evaluating the safety and efficacy of Chemotherapy-immunotherapy-based split-course adaptive hypofractionated radiotherapy for extensive-stage SCLC

Conditions

  • Small-cell Lung Cancer

Interventions

RADIATION

split-course adaptive hypofractionated radiotherapy

Each treatment cycle comprises a solitary radiotherapy session, which allows for its integration with chemotherapy and immunotherapy. The radiotherapy sessions are scheduled at three-week intervals, thereby affording extended recovery periods for normal tissues. An adaptive radiotherapy plan is implemented for each cycle, enabling precise adjustments to the treatment target area in response to the reduction in tumor volume.

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-26
Primary Completion
2026-10-31
Completion
2028-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06816966 on ClinicalTrials.gov